



## MISSION AND VISION STATEMENT

The Global Health EDCTP3 Joint Undertaking supports global collaborative research, capacity strengthening, and international initiatives to accelerate the development, evaluation, and implementation of interventions to prevent, identify, and treat infectious diseases and emerging/re-emerging infections in sub-Saharan Africa with the overarching goal to reduce overall mortality and morbidity.

The partnership's general objectives are to:

- reduce the socio-economic burden of infectious diseases in sub-Saharan Africa promoting the development and uptake of new or improved health technologies;
- increase health security in sub-Saharan Africa and globally by strengthening the research and innovation-based capacities for preparedness and response to control infectious diseases.

## KEY FACTS AND FIGURES

**Horizon Europe Pillar and Cluster:** Pillar II – Cluster 1: Health

**Type of Partnership:** Institutionalised (Art 187 TFEU) – joint undertaking

**Coordinating entity:** EDCTP3 members are represented by the EDCTP Association

**Total estimated budget:** EUR 1.6 bn

**EU commitments:** up to EUR 800 m

**Partners' commitments:** EUR 839 m\*

**Predecessor under Horizon 2020:** EDCTP 1 and EDCTP2

\* Out of which the members of the JU (EDCTP Association) is expected to contribute at least EUR 439 m and contributing partners EUR 400 m

## FIND OUT MORE

<https://www.edctp.org/>

[https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/edctp\\_en](https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/edctp_en)


@EDCTP

[EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu](mailto:EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu)



**PARTNERSHIP SPECIFIC IMPACT PATHWAY (PSIP)**

**PARTNERSHIP VISION: CONTRIBUTE TO SOCIETAL CHALLENGES THROUGH ...**



ID: infectious diseases  
SSA: sub-Saharan Africa


**PARTNERSHIP'S KEY PERFORMANCE INDICATORS**

KPI NAME	UNIT OF MEASUREMENT	BASELINE	TARGET 2023	TARGET 2025	TARGET 2027	AMBITION >2027
<b>RESOURCES (INPUT), PROCESSES AND ACTIVITIES</b>						
Investment in clinical trials	Funding (euro) # of projects (RIA)	EDCTP2	TBD	TBD	TBD	Sustained & increased
Investment in R&I coordination	Funding (euro)	EDCTP2	TBD	TBD	TBD	Sustained & increased
Capacity building in Sub-Saharan Africa (SSA)	Funding (euro) fellowships; funding other capacity building activities <sup>1</sup>	EDCTP2	TBD	TBD	TBD	Strengthened
Strategic partnerships development	# of partnerships	EDCTP2	TBD	TBD	TBD	Strengthened
<b>OUTCOMES</b>						
Development of health technologies	# licensed # advanced	EDCTP2	TBD	TBD	TBD	Increased
R&I capacity in infectious diseases in SSA	# publications external funding (euro)	EDCTP2	TBD	TBD	TBD	Strengthened
R&I epidemic preparedness in SSA	Funding (euro) invested; # projects	EDCTP2	TBD	TBD	TBD	Strengthened
Cost-effectiveness of public investment	# co-funded activities; # of additional activities between Member States	EDCTP2	TBD	TBD	TBD	Increased
Sustainable global health research networks	# of participating countries and institutions; Funding (euro) in third party contributions	EDCTP2	TBD	TBD	TBD	Increased
<b>IMPACTS</b>						
Burden of infectious diseases (IDs) in SSA <sup>2</sup>	Mortality caused by IDs in SSA  Disability-adjusted life years (DALYs) caused by IDs in SSA	WHO Mortality Data <a href="https://www.who.int/mortality/country-profile">Mortality Country profile (who.int)</a>  WHO data on the burden of disease <a href="https://www.who.int/global-health-estimates/leading-causes-of-dalys">Global health estimates: Leading causes of DALYs (who.int)</a>	N/A	N/A	N/A	Reduced
Health security	Average capacity of SSA countries to develop & maintain International Health Regulations (IHR)	As of October 2021, the WHO AFRO region had a 49 % average capacity <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">e-SPAR Public (who.int)</a>	N/A	N/A	N/A	Increased

<sup>1</sup> EDCTP funds other capacity building activities aside from fellowships, such as activities in the area of strengthening ethics and regulatory capacity in SSA.

<sup>2</sup> Although the units of measurement selected for this impact do allow measuring whether the burden of IDs have increased/decreased, this burden is multi-factorial and thus the work and investment by EDCTP alone cannot decrease this burden.

General note to the reader: These KPIs have been simplified for the sake of clarity. Further details on the Global Health EDCTP3-specific KPIs can be found in the Strategic Research and Innovation Agenda, available here: [https://ec.europa.eu/info/sites/default/files/research\\_and\\_innovation/research\\_by\\_area/documents/ec\\_rtd\\_edctp3-sria-2022.pdf](https://ec.europa.eu/info/sites/default/files/research_and_innovation/research_by_area/documents/ec_rtd_edctp3-sria-2022.pdf)



## SYNERGIES WITH OTHER EUROPEAN AND NATIONAL INITIATIVES

Due to its versatility and cross-sectoral integration, the Global Health EDCTP3 should be managed through close collaboration with other programmes and initiatives to create synergies and limit duplications. It is essential to design administrative mechanisms to appropriately address these synergies and complementarities. Synergies will be sought with the following European Partnerships:

- Innovative Health Initiative (IHI)
- One Health AMR
- Animal Health and Welfare
- Transformation of Health Care Systems
- Fostering an ERA for Health Research
- Key Digital Technologies
- High Performance Computing
- Smart Networks and Services.

### SYNERGIES: STORY 1

Partnership with the World Health Organization (WHO): WHO is a key partner for EDCTP and collaboration is happening at strategic and technical levels, with EDCTP staff actively participating in several WHO policy and technical advisory group meetings. EDCTP representatives participate in a variety of committees and working groups established by WHO, including the WHO R&D Blueprint Global Coordination Mechanism, several workstreams coordinated by the WHO Global Malaria Programme to address the double challenge of malaria & COVID-19, and the WHO-AFRO Expert Committee on Traditional Medicine for COVID-19.

### SYNERGIES: STORY 2

EDCTP became an active member of the ESSENCE on Health Research platform in 2020, an initiative that allows donors and funders to identify synergies, establish coherence and increase the value of resources for health research. EDCTP contributed to 1) the ESSENCE Working Group of Review of Investments (WGRI), which is developing a coordination mechanism for reviewing investments in clinical research capacity building in response to the World Bank and Coalition for Epidemic Preparedness and Innovation (CEPI) report *Money and Microbes: Strengthening Research Capacity to Prevent Epidemics*; as well as 2) the publishing and dissemination of a good practice document to guide funders on the best ways to invest in implementation science.

### SYNERGIES: STORY 3

In September 2020, EDCTP became a member-observer of the Global Research Collaboration for Infectious Disease Preparedness GloPID-R network, an alliance bringing together research funding organisations on a global scale to facilitate effective and rapid research to address a significant outbreak of a new or re-emerging infectious disease with epidemic and pandemic potential.

## OVERVIEW OF MEMBERS

*Not available*